BCL2 and breast cancer: The levels of β-catenin, Bcl2, and CDK2 decreased in breast cancer cells treated with MeCP2 siRNAs compared to those with control siRNA, whereas the expression levels of Bax, P21, and P53 increased (Fig. 1k).